Insider Selling: Tango Therapeutics (NASDAQ:TNGX) Insider Sells 7,031 Shares of Company Stock

Key Points

• Insider Jessica Newcomb sold 7,031 Tango Therapeutics shares at an average of $22.42, totaling about $157,635. After the sale, she directly owned 52,090 shares.
• Tango Therapeutics’ latest reported quarterly loss was $0.37 per share, missing analysts’ $0.32-per-share loss estimate; analysts expect a loss of $1.41 per share for the current year.
• Analyst sentiment is broadly positive: 13 analysts rate the stock Buy, and its consensus rating is Moderate Buy with a $44.62 average price target.

Tango Therapeutics, Inc. (NASDAQ:TNGX - Get Free Report) insider Jessica Newcomb sold 7,031 shares of the firm's stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $22.42, for a total transaction of $157,635.02. Following the sale, the insider directly owned 52,090 shares in the company, valued at approximately $1,167,857.80. The trade was a 11.89% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Jessica Newcomb also recently made the following trade(s):

• On Tuesday, September 22nd, Jessica Newcomb sold 8,200 shares of Tango Therapeutics stock. The stock was sold at an average price of $24.22, for a total transaction of $198,604.00.

Tango Therapeutics Stock Up 0.0%

Tango Therapeutics stock traded up $0.01 during midday trading on Wednesday, reaching $23.18. 2,464,255 shares of the company traded hands, compared to its average volume of 4,639,952. Tango Therapeutics, Inc. has a 12 month low of $7.37 and a 12 month high of $34.39. The business has a 50 day moving average of $23.50 and a two-hundred day moving average of $22.39.

Tango Therapeutics (NASDAQ:TNGX - Get Free Report) last posted its earnings results on Tuesday, August 11th. The company reported ($0.37) EPS for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.05). Research analysts anticipate that Tango Therapeutics, Inc. will post -1.41 EPS for the current year.

Hedge Funds Weigh In On Tango Therapeutics

Institutional investors have recently bought and sold shares of the stock. BlackRock Inc. purchased a new position in Tango Therapeutics during the second quarter valued at $388,826,000. TRV GP IV LLC purchased a new stake in Tango Therapeutics in the second quarter worth about $120,181,383,000. Jupiter Topco LLC purchased a new stake in Tango Therapeutics in the second quarter worth about $157,989,000. Seven Fleet Capital Management LP raised its stake in shares of Tango Therapeutics by 302.2% in the second quarter. Seven Fleet Capital Management LP now owns 3,228,144 shares of the company's stock worth $95,661,000 after buying an additional 2,425,484 shares during the period. Finally, Jefferies Financial Group Inc. bought a new position in shares of Tango Therapeutics in the second quarter worth about $62,849,000. 78.99% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages recently commented on TNGX. HC Wainwright reaffirmed a "buy" rating and issued a $68.00 price objective on shares of Tango Therapeutics in a report on Thursday, October 29th. Stifel Nicolaus set a $55.00 target price on Tango Therapeutics in a report on Friday, October 23rd. William Blair assumed coverage on Tango Therapeutics in a research report on Friday, October 16th. They issued an "outperform" rating on the stock. Weiss Ratings upgraded Tango Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Tuesday, August 11th. Finally, Guggenheim upped their price target on shares of Tango Therapeutics from $32.00 to $35.00 and gave the company a "buy" rating in a research report on Wednesday, August 12th. Thirteen research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have given a Sell rating to the company's stock. According to MarketBeat, Tango Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus target price of $44.62.

Tango Therapeutics Company Profile

Tango Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing medicines for cancer. The company uses functional genomics and genetic screening to identify vulnerabilities in tumor cells, including dependencies created by tumor-suppressor gene loss, and to develop targeted therapies designed to selectively attack cancer cells.

Tango's pipeline includes small-molecule programs for genetically defined solid tumors. Its lead program, TNG462, is an MTA-cooperative PRMT5 inhibitor being developed for cancers with MTAP gene deletions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.